Subsequent entry biologics/biosimilars: a viewpoint from Canada
We have reviewed the issues surrounding the advent of biosimilars in the rheumatoid arthritis biologic field. Our proposals emphasize the need to focus primarily on patient safety and to assess the outcomes of therapy both in the short and longer term.
KeywordsBiosimilars Subsequent entry biologics
- 4.Sekhon BS, Saluja V (2011) Biosimilars: an overview. Biosimilars 1:1–11Google Scholar
- 5.Kogan LA (2011) The US biologics price competition and Innovation Act of 2009 triggers public debate, regulatory/policy risks and international trade concerns. Global Trade Customs J 6:1–34Google Scholar
- 9.Gu N, Yi S, Kim T-E, Shin S-G, Jang I-J, Yu K-S (2011) Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence cross-over study in healthy Korean male volunteers. Clin Therapeutics 33:2029–2037CrossRefGoogle Scholar